In:
Cancer Science, Wiley, Vol. 108, No. 12 ( 2017-12), p. 2495-2502
Abstract:
There are no blood biomarkers for the diagnosis of renal cell carcinoma ( RCC ) in routine clinical use. We focused on the gene expression profile of peripheral blood cells obtained from RCC patients to discover novel biomarkers for RCC diagnosis. Using microarray analysis and quantitative verification, CXCL 7 was shown to be significantly upregulated in the peripheral blood cells of RCC patients. Importantly, aberrant CXCL 7 expression was confirmed even in peripheral blood cells obtained from early stage ( pT 1a) RCC patients, and the expression level of CXCL 7 in peripheral blood cells was a potential independent biomarker for the diagnosis of RCC by receiver operating characteristic curve analysis (sensitivity, 70.0%; specificity, 64.0%; area under the curve = 0.722; multiple logistic regression analysis: odds ratio, 1.07; 95% confidence interval, 1.03–1.11; P = 0.0004). Moreover, CXCL 7 expression in peripheral blood cells significantly decreased after resection of the primary tumor. CXCL 7 is more highly expressed in PBMC s than in neutrophils from both healthy controls and RCC patients. Interestingly, CXCL 7 expression in PBMC s from healthy volunteers was significantly elevated following coculture with RCC cells compared to those cocultured with normal cells as a control. These results suggest that aberrant CXCL 7 expression in peripheral blood cells is induced by RCC cells and may serve as a novel biomarker in the diagnosis of RCC .
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2017.108.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Permalink